Tiziana Life Sciences is a dual-listed (NASDAQ:TLSA, AIM:TILS) clinical stage biotechnology company that specializes in the developing transformative therapies for inflammatory diseases and cancer related to the liver. Our clinical pipeline includes drug assets for NASH, Crohn's, and hepatocellular carcinoma. Tiziana is led by a team of highly qualified executives with extensive drug development and commercialization experience.
Our mission is to bring breakthrough therapies to patients with the aim of reversing severe liver diseases and optimizing health outcomes.
We envision becoming a leader in advancing innovative, best-in-class medicines for patients with life threatening liver diseases.
View our investor report for 2018 Investors Annual Report 2018
Milciclib is the Company’s Phase 2 clinical candidate for the treatment of multiple cancer indications such as hepatocellular carcinoma, thymic cancer and thymoma. Milciclib, a pan cyclin-dependent kinases (CDK) inhibitor, has demonstrated potent anti-tumor activity as a monotherapy as well as combination therapy.
Foralumab is a fully human anti-CD3 monoclonal antibody (mAb) for the treatment of NASH, Crohn’ s Disease and as a neurodegenerative indicator. It has completed Phase 2 studies in Crohn’s disease. Foralumab has demonstrated ability to activate regulatory T cells that systemically circulate to elicit targeted immunomodulation providing therapeutic benefit to patients.